The current status of scientific research and hormonal treatments for carcinoma of the prostate
Open Access
- 1 September 1991
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 64 (3) , 419-421
- https://doi.org/10.1038/bjc.1991.324
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Suppression of Tumorigenicity of Human Prostate Carcinoma Cells by Replacing a Mutated RB GeneScience, 1990
- Three‐monthly GnRH Agonist (Buserelin) for Prostatic CancerBritish Journal of Urology, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patientsJournal of Steroid Biochemistry, 1987
- Gonadotrophin hormone releasing analogues open new doors in cancer treatment.BMJ, 1987
- Androgen Suppression by Hydrocortisone without Aminoglutethimide in Orchiectomised Men with Prostatic CancerBritish Journal of Urology, 1987
- Expression ofrasOncogene p21 in Prostate CancerNew England Journal of Medicine, 1986
- Expression of cellular oncogenes in human prostatic carcinoma cell linesBiochemical and Biophysical Research Communications, 1985
- Advanced prostatic carcinoma Flutamide therapy after conventional endocrine treatmentUrology, 1975
- THE PRESENT POSITION OF THE SURGERY OF THE HYPERTROPHIED PROSTATEAnnals of Surgery, 1893